Evidence map›Paper›PMID 28446503›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.

Eben L Rosenthal, Lindsay S Moore, Kiranya Tipirneni, Esther de Boer, Todd M Stevens, Yolanda E Hartman, William R Carroll, Kurt R Zinn, Jason M Warram

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04161560 (Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer), which is not on this map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04161560 phase1unknown statusnot on this mapstarted 2019, after this paper: background citation

Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer:A Single Center Clinical Research

TypeinterventionalSponsorFifth Affiliated Hospital, Sun Yat-Sen UniversityRan2019 to 2021Enrolled40ConditionsDrug Safety, Drug SpecificityArmsCetuximab-IRDye800
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  3. Trial
  4. Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  5. Trial
  6. Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Trial
  7. Trial
  8. Trial
  9. More Than a Glow: How Cyanine Dyes Shape Tracer Pharmacokinetics.Angewandte Chemie (International ed. in English) · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Eben L RosenthalDepartment of Otolaryngology, Stanford University, Stanford, California. ERosenthal@stanfordhealthcare.org.
Lindsay S MooreDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama.
Kiranya TipirneniDepartment of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Esther de BoerDepartment of Surgery, University Medical Center Groningen University of Groningen, Groningen, the Netherlands.
Todd M StevensDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Yolanda E HartmanDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama.
William R CarrollDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama.
Kurt R ZinnDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
Jason M WarramDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama.
University of Alabama at Birmingham · US

Funding

Research Training Program in Surgical OncologyT32CA091078 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KENNEDY, GREGORY DEAN · 2002 to 2017
$4.8M
Prototype optical device for image guided surgery with panitumumab-IRDye800R01CA190306 · NCI · STANFORD UNIVERSITY · PI ROSENTHAL, EBEN L. · 2015 to 2019
$2.6M
Imaging Guided Surgery using Fluorescently Labeled CetuximabR21CA182953 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CARROLL, WILLIAM, WARRAM, JASON MORGAN · 2014 to 2015
$536k
NCI NIH HHS R01 CA190306NCI NIH HHS R21 CA182953NCI NIH HHS T32 CA091078
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalBenzenesulfonatesCetuximabCombined Modality TherapyDiagnostic ImagingFemaleFluorescenceHead and Neck NeoplasmsHumansIndolesLymphatic MetastasisLymph Node ExcisionMaleAntineoplastic Agents, ImmunologicalBenzenesulfonatesCetuximabIndolesIRDye 800CW

Identifiers

PMID28446503
PMCPMC5595145
OpenAlexW2608695549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.